

# Ipsen Public Policy Activities Statement



## Introduction

At Ipsen, we believe we have a responsibility to help shape public policy and regulatory frameworks that enable medical innovation and serve patients with high unmet needs. By engaging in open dialogue with policymakers, institutions, and other stakeholders, we work collaboratively to foster an environment that accelerates access to life-changing treatments. Our goal is to ensure that the realities of patient care are reflected in policy – enabling better, faster, and fairer access to innovative therapies.

## Our approach

Our public policy work focuses on ensuring timely and equitable access to innovative treatments, especially for people living with rare or underserved conditions. We engage constructively with policymakers and stakeholders at national, regional, and global levels to advance policies that promote patient access and encourage scientific progress. Ipsen strictly adheres to all applicable anti-corruption laws and transparency obligations, in line with our [Code of Conduct](#). Our activities are grounded in ethical standards, integrity, and respect for democratic decision-making processes.

## Our general principles

- We operate transparently and in compliance with the laws, regulations and codes on interactions with policymakers, and driven by the highest ethical standards in the best interest of patients.
- We expect the policymakers we interact with to be compliant with the transparency and disclosure rules that apply to them, including those of the institutions they cooperate with.
- We provide policymakers with information that is fair, balanced and substantiated to enable them to exercise the best possible judgement in creating and implementing policies in the interest of patients and society.
- We do not influence policymakers inappropriately through misleading information or offer anything of value to obtain favorable treatment for Ipsen or its products.
- We require suppliers to adhere to our Business Partner Code of Conduct and to demonstrate their compliance through regular assessments.

Our compliance with these principles is unwavering, and we take any violations seriously.

## Trade association management system

As a global biopharmaceutical actor, Ipsen is a member of different global, regional and national trade associations. To ensure consistency and respect for our commitments, we have implemented an internal management system to oversee our public policy activities and trade association memberships. This system tracks our annual monetary contributions and other political expenditures, ensuring adherence to the highest standards of ethical conduct and transparency.

## Transparency and reporting

In line with our commitment to transparency, Ipsen discloses its global spending on public policy engagement, trade associations, and political contributions. These figures reflect our intent to contribute constructively to the policy landscape, always within legal and ethical frameworks. Ipsen reports public policy activities in regional and national Transparency Registers, where present. For FY2024, Ipsen's expenditures for public

policy activities in regions and countries with a commercial presence<sup>1</sup>, political contributions and trade associations are itemized below.



| CONTRIBUTIONS & OTHER SPENDING                                  | FY2024               |
|---|----------------------|
| Lobbying, interest representation or similar                    | 1'083'196 EUR        |
| Local, regional or national political campaigns / candidates    | Not applicable       |
| Trade associations or tax-exempt groups                         | 3'954'990 EUR        |
| Other (e.g. spending related to ballot measures or referendums) | Not applicable       |
| <b>TOTAL</b>  | <b>5'038'186 EUR</b> |

| LARGEST CONTRIBUTIONS & EXPENDITURES                 |                    |   |                       |
|--|--------------------|---|-----------------------|
| Issue or topic                                       | Corporate position | Description of position/ engagement   | Total spent in FY2024 |
| Policies on rare disease, neurosciences and oncology | Support            | Ipsen engages in advocacy and awareness activities to promote access pathways to innovative therapies in its key therapeutic areas, oncology, rare disease and neurosciences. This includes, but is not limited to, support innovation in rare disease, improved care pathways for patients with post-stroke spasticity, and improved access to combination therapies in oncology. Engagements include scientific and policy sponsorships, multistakeholder coalition work, regional policy dialogues, awareness campaigns, and media partnerships to amplify patient and caregiver perspectives. | 479'500 EUR           |

## Conclusion

Ipsen's public policy and political engagement activities are grounded in our mission to serve patients and contribute to a sustainable innovation-friendly ecosystem. We will continue to evolve our ways of working to meet the highest standards of integrity, transparency, and impact — and to be a trusted voice in shaping the future of healthcare.

<sup>1</sup> Including: Algeria, Asian-Pacific Region (Australia, Malaysia, New Zealand, South Korea, Singapore, Taiwan), Australia, Austria, Belgium, China, Czech Republic, Denmark, France, Finland, Germany, Hungary, Italy, Ireland, Mexico, New Zealand, Poland, The Netherlands, Romania, Slovakia, Spain, Sweden, Switzerland, Tunisia, The United States, The United Kingdom. Above countries contributions and expenditures are included in the FY2024 amounts.